Key features and details
- Rabbit polyclonal to FOXN3
- Suitable for: WB, IP
- Reacts with: Human
- Isotype: IgG
Product nameAnti-FOXN3 antibody
See all FOXN3 primary antibodies
DescriptionRabbit polyclonal to FOXN3
Tested applicationsSuitable for: WB, IPmore details
Species reactivityReacts with: Human
Predicted to work with: Rabbit, Horse, Chicken, Guinea pig, Dog, Pig, Chimpanzee, Rhesus monkey, Gorilla, Orangutan, Platypus
Synthetic peptide corresponding to Human FOXN3 aa 440-490.
Database link: NP_001078940.1
- WB: Jurkat, HEK-293T and HeLa whole cell lysates.
This product was previously labelled as CHES1
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
Storage bufferpH: 7
Preservative: 0.09% Sodium azide
Constituent: 99% PBS
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab129453 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/2000 - 1/10000. Predicted molecular weight: 54 kDa.|
|IP||Use at 2-10 µg/mg of lysate.|
FunctionActs as a transcriptional repressor. May be involved in DNA damage-inducible cell cycle arrests (checkpoints).
Sequence similaritiesContains 1 fork-head DNA-binding domain.
- Information by UniProt
- C14orf116 antibody
- Checkpoint suppressor 1 antibody
- CHES1 antibody
All lanes : Anti-FOXN3 antibody (ab129453) at 0.1 µg/ml
Lane 1 : Jurkat whole cell lysate at 50 µg
Lane 2 : Jurkat whole cell lysate at 15 µg
Lane 3 : 293T whole cell lysate at 50 µg
Lane 4 : HeLa whole cell lysate at 50 µg
Developed using the ECL technique.
Predicted band size: 54 kDa
Exposure time: 3 minutes
Detection of FOXN3 by Western Blot of Immunprecipitate.
Lane 1: ab129453 at 1µg/ml staining FOXN3 in HeLa whole cell lysate immunoprecipitated using ab129453 at 6µg/mg lysate (1 mg/IP; 20% of IP loaded/lane).
Lane 2: Control IgG
Detection: Chemiluminescence with exposure time of 30 seconds.
ab129453 has been referenced in 4 publications.
- He H et al. Novel tumor-suppressor FOXN3 is downregulated in adult acute myeloid leukemia. Oncol Lett 18:1521-1529 (2019). PubMed: 31423219
- Xu Z et al. Checkpoint suppressor 1 suppresses transcriptional activity of ERa and breast cancer cell proliferation via deacetylase SIRT1. Cell Death Dis 9:559 (2018). PubMed: 29752474
- Sun M et al. MicroRNA-378 regulates epithelial-mesenchymal transition and metastasis of melanoma by inhibiting FOXN3 expression through the Wnt/ß-catenin pathway. Cell Biol Int N/A:N/A (2018). PubMed: 29972255
- Li W et al. The FOXN3-NEAT1-SIN3A repressor complex promotes progression of hormonally responsive breast cancer. J Clin Invest 127:3421-3440 (2017). PubMed: 28805661